DE69635848T2 - Verfahren zum Nachweis von Ki-ras Mutationen - Google Patents
Verfahren zum Nachweis von Ki-ras Mutationen Download PDFInfo
- Publication number
- DE69635848T2 DE69635848T2 DE69635848T DE69635848T DE69635848T2 DE 69635848 T2 DE69635848 T2 DE 69635848T2 DE 69635848 T DE69635848 T DE 69635848T DE 69635848 T DE69635848 T DE 69635848T DE 69635848 T2 DE69635848 T2 DE 69635848T2
- Authority
- DE
- Germany
- Prior art keywords
- mutations
- ras
- mutation
- pcr
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 173
- 238000000034 method Methods 0.000 title claims abstract description 103
- 102100030708 GTPase KRas Human genes 0.000 title claims abstract description 61
- 101710113436 GTPase KRas Proteins 0.000 title claims abstract description 61
- 238000001514 detection method Methods 0.000 title claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 73
- 108020004705 Codon Proteins 0.000 claims abstract description 29
- 238000012408 PCR amplification Methods 0.000 claims abstract description 12
- 230000029142 excretion Effects 0.000 claims abstract 4
- 230000018528 secretion by tissue Effects 0.000 claims abstract 4
- 239000013615 primer Substances 0.000 claims description 83
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 37
- 230000000295 complement effect Effects 0.000 claims description 22
- 239000000499 gel Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 239000003155 DNA primer Substances 0.000 claims description 8
- 210000001072 colon Anatomy 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 2
- 238000004140 cleaning Methods 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 abstract description 13
- 210000001519 tissue Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000007844 allele-specific PCR Methods 0.000 abstract 1
- 210000002751 lymph Anatomy 0.000 abstract 1
- 238000003752 polymerase chain reaction Methods 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 55
- 150000007523 nucleic acids Chemical class 0.000 description 55
- 108020004707 nucleic acids Proteins 0.000 description 51
- 102000039446 nucleic acids Human genes 0.000 description 51
- 239000000047 product Substances 0.000 description 37
- 210000003608 fece Anatomy 0.000 description 33
- 239000000523 sample Substances 0.000 description 23
- 230000003321 amplification Effects 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000002052 colonoscopy Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 208000003200 Adenoma Diseases 0.000 description 9
- 238000006116 polymerization reaction Methods 0.000 description 9
- 108700042226 ras Genes Proteins 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000009826 neoplastic cell growth Effects 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 108010006785 Taq Polymerase Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000007857 nested PCR Methods 0.000 description 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000010437 gem Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical class C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- -1 nucleotide triphosphates Chemical class 0.000 description 2
- 210000001819 pancreatic juice Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012985 polymerization agent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000027204 Cystic pancreatic disease Diseases 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical class CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Electrophonic Musical Instruments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control And Other Processes For Unpacking Of Materials (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Holo Graphy (AREA)
- Saccharide Compounds (AREA)
- Electrically Operated Instructional Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO954667 | 1995-11-17 | ||
| NO954667A NO954667D0 (no) | 1995-11-17 | 1995-11-17 | Fremgangsmåte til deteksjon av Ki-ras mutasjoner |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69635848D1 DE69635848D1 (de) | 2006-04-27 |
| DE69635848T2 true DE69635848T2 (de) | 2006-11-30 |
Family
ID=19898772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69635848T Expired - Fee Related DE69635848T2 (de) | 1995-11-17 | 1996-11-15 | Verfahren zum Nachweis von Ki-ras Mutationen |
| DE69630234T Expired - Fee Related DE69630234T2 (de) | 1995-11-17 | 1996-11-15 | Verfahren zur bestimung von ki-ras mutationen und dieses leistender testsatz |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69630234T Expired - Fee Related DE69630234T2 (de) | 1995-11-17 | 1996-11-15 | Verfahren zur bestimung von ki-ras mutationen und dieses leistender testsatz |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6440661B1 (enExample) |
| EP (2) | EP0868529B1 (enExample) |
| JP (1) | JP2000500346A (enExample) |
| AT (2) | ATE318934T1 (enExample) |
| AU (1) | AU723980C (enExample) |
| DE (2) | DE69635848T2 (enExample) |
| DK (2) | DK0868529T3 (enExample) |
| ES (2) | ES2262930T3 (enExample) |
| NO (2) | NO954667D0 (enExample) |
| NZ (1) | NZ322619A (enExample) |
| PT (2) | PT868529E (enExample) |
| WO (1) | WO1997019191A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9715034D0 (en) * | 1997-07-18 | 1997-09-24 | Zeneca Ltd | Assay |
| DE60029092T2 (de) * | 1999-04-09 | 2007-02-01 | Exact Sciences Corp., Marlborough | Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen |
| US6531302B1 (en) * | 1999-04-12 | 2003-03-11 | Nanogen/Becton Dickinson Partnership | Anchored strand displacement amplification on an electronically addressable microchip |
| US6849403B1 (en) | 1999-09-08 | 2005-02-01 | Exact Sciences Corporation | Apparatus and method for drug screening |
| US6586177B1 (en) | 1999-09-08 | 2003-07-01 | Exact Sciences Corporation | Methods for disease detection |
| CA2394921A1 (en) | 1999-12-07 | 2001-06-14 | Anthony P. Shuber | Supracolonic aerodigestive neoplasm detection |
| US7087414B2 (en) | 2000-06-06 | 2006-08-08 | Applera Corporation | Methods and devices for multiplexing amplification reactions |
| US6605451B1 (en) * | 2000-06-06 | 2003-08-12 | Xtrana, Inc. | Methods and devices for multiplexing amplification reactions |
| EP2351853A1 (en) * | 2000-06-06 | 2011-08-03 | Life Technologies Corporation | Method and devices for multiplexing amplification reactions |
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| US8323897B2 (en) | 2002-12-04 | 2012-12-04 | Applied Biosystems, Llc | Multiplex amplification of polynucleotides |
| WO2005113769A1 (en) * | 2004-05-14 | 2005-12-01 | Exact Sciences Corporation | Method for stabilizing biological samples for nucleic acid analysis |
| US20070134709A1 (en) * | 2005-12-14 | 2007-06-14 | Xiping Xu | Usages of MTHFR gene polymorphisms in predicting homocysteine level, disease risk, and treatment effects and related methods and kit |
| GB2435512A (en) | 2006-02-23 | 2007-08-29 | Mologic Ltd | A binding assay and assay device |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| AU2007253740A1 (en) | 2006-05-18 | 2007-11-29 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
| GB2467691A (en) | 2008-09-05 | 2010-08-11 | Aueon Inc | Methods for stratifying and annotating cancer drug treatment options |
| JP2012508577A (ja) | 2008-11-12 | 2012-04-12 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 表現型を決定するためのエキソソームの使用方法およびそのシステム |
| US20130005598A1 (en) * | 2009-12-31 | 2013-01-03 | The Regents Of The University Of Michigan | Methods for Diagnosing The Malignant Potential of Pancreatic Cystic Lesions |
| US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| CN103228798B (zh) | 2010-09-24 | 2015-12-09 | 斯坦福大学托管董事会 | 使用固定的引物直接捕获、扩增及测序靶标dna |
| GB201107466D0 (en) | 2011-05-05 | 2011-06-15 | Loktionov Alexandre | Device and method for non-invasive collection of colorectal mucocellular layer and disease detection |
| CN102796811B (zh) * | 2011-05-26 | 2013-12-18 | 上海赛安生物医药科技有限公司 | 检测kras突变的试剂及方法 |
| US9442046B2 (en) | 2011-06-19 | 2016-09-13 | Abogen, Inc. | Device for sample collection |
| EP2780473B1 (en) * | 2011-11-17 | 2017-07-19 | The Johns Hopkins University | Differential identification of pancreatic cysts |
| CA2893158A1 (en) * | 2012-11-30 | 2014-06-05 | Applied Proteomics, Inc. | Method for evaluation of presence of or risk of colon tumors |
| AU2015226811B2 (en) | 2014-03-07 | 2021-07-15 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
| CA2982169A1 (en) | 2015-04-10 | 2016-10-13 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
| US10753936B2 (en) | 2016-07-22 | 2020-08-25 | Van Andel Research Institute | Method of detecting the level of a glycan |
| TW202015719A (zh) | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4871838A (en) * | 1985-07-23 | 1989-10-03 | The Board Of Rijks Universiteit Leiden | Probes and methods for detecting activated ras oncogenes |
| US5137806A (en) * | 1989-12-11 | 1992-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection of sequences in selected DNA molecules |
| IL97222A (en) * | 1990-02-16 | 1995-08-31 | Orion Yhtymae Oy | Method and reagent for determining specific nucleotide variations |
| WO1993020235A1 (en) | 1992-04-01 | 1993-10-14 | The Johns Hopkins University School Of Medicine | Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor |
| CA2134552A1 (en) * | 1992-04-27 | 1993-11-11 | George D. Sorenson | Detection of gene sequences in biological fluids |
| JPH06167492A (ja) * | 1992-11-30 | 1994-06-14 | Otsuka Pharmaceut Co Ltd | 変異癌遺伝子の検出測定方法 |
| DE19512369A1 (de) * | 1995-04-01 | 1996-10-02 | Boehringer Mannheim Gmbh | Vorrichtung zur Isolierung von Nukleinsäuren |
-
1995
- 1995-11-17 NO NO954667A patent/NO954667D0/no unknown
-
1996
- 1996-11-15 WO PCT/NO1996/000271 patent/WO1997019191A1/en not_active Ceased
- 1996-11-15 AU AU76569/96A patent/AU723980C/en not_active Ceased
- 1996-11-15 ES ES03020560T patent/ES2262930T3/es not_active Expired - Lifetime
- 1996-11-15 EP EP96939373A patent/EP0868529B1/en not_active Expired - Lifetime
- 1996-11-15 JP JP9519622A patent/JP2000500346A/ja active Pending
- 1996-11-15 ES ES96939373T patent/ES2208766T3/es not_active Expired - Lifetime
- 1996-11-15 AT AT03020560T patent/ATE318934T1/de not_active IP Right Cessation
- 1996-11-15 PT PT96939373T patent/PT868529E/pt unknown
- 1996-11-15 EP EP03020560A patent/EP1394272B1/en not_active Expired - Lifetime
- 1996-11-15 AT AT96939373T patent/ATE251222T1/de not_active IP Right Cessation
- 1996-11-15 US US09/068,805 patent/US6440661B1/en not_active Expired - Fee Related
- 1996-11-15 DE DE69635848T patent/DE69635848T2/de not_active Expired - Fee Related
- 1996-11-15 PT PT03020560T patent/PT1394272E/pt unknown
- 1996-11-15 DE DE69630234T patent/DE69630234T2/de not_active Expired - Fee Related
- 1996-11-15 DK DK96939373T patent/DK0868529T3/da active
- 1996-11-15 NZ NZ322619A patent/NZ322619A/xx unknown
- 1996-11-15 DK DK03020560T patent/DK1394272T3/da active
-
1998
- 1998-05-15 NO NO19982246A patent/NO324963B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1394272E (pt) | 2006-07-31 |
| EP0868529B1 (en) | 2003-10-01 |
| ES2208766T3 (es) | 2004-06-16 |
| US6440661B1 (en) | 2002-08-27 |
| NO954667D0 (no) | 1995-11-17 |
| NO324963B1 (no) | 2008-01-14 |
| DK1394272T3 (da) | 2006-07-03 |
| EP1394272B1 (en) | 2006-03-01 |
| DE69630234T2 (de) | 2004-08-19 |
| ATE251222T1 (de) | 2003-10-15 |
| AU723980B2 (en) | 2000-09-07 |
| EP1394272A1 (en) | 2004-03-03 |
| ES2262930T3 (es) | 2006-12-01 |
| NO982246D0 (no) | 1998-05-15 |
| JP2000500346A (ja) | 2000-01-18 |
| DK0868529T3 (da) | 2004-02-02 |
| DE69630234D1 (de) | 2003-11-06 |
| WO1997019191A1 (en) | 1997-05-29 |
| AU7656996A (en) | 1997-06-11 |
| ATE318934T1 (de) | 2006-03-15 |
| NZ322619A (en) | 1999-04-29 |
| PT868529E (pt) | 2004-02-27 |
| DE69635848D1 (de) | 2006-04-27 |
| NO982246L (no) | 1998-07-07 |
| AU723980C (en) | 2002-10-24 |
| EP0868529A1 (en) | 1998-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69635848T2 (de) | Verfahren zum Nachweis von Ki-ras Mutationen | |
| DE69333289T2 (de) | Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien | |
| DE69223284T2 (de) | Methoden zur Bestimmung von Krebsmetastasen mittels Nukleinsäuren-Amplifikation | |
| DE69433816T2 (de) | Die bestimmung von nukleinsäuremutationen durch analyse des sputum | |
| DE60030281T2 (de) | Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen | |
| DE69735894T2 (de) | Spezifische bestimmung der methylierung | |
| US6465177B1 (en) | Detection of loss of heterozygosity in tumor and serum of melanoma patients | |
| US7279312B2 (en) | Nucleic acid mutation detection by analysis of saliva | |
| DE69619864T2 (de) | Verfahren zur amplifizierung spezifischer nukleinsäuresequenzen | |
| DE69230736T2 (de) | Verfahren zur Charakterisierung genomischer DNA | |
| US20130149695A1 (en) | Method for detecting genetic mutation by using a blocking primer | |
| Ohshima et al. | Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung | |
| JPH10506527A (ja) | 組織中の高変異可能な核酸配列の検出 | |
| DE60113945T2 (de) | Verfahren zur Analyse von Wiederkehrenden PCR-Podukten, das auf der Analyse von DNS-Schmelzkurven basiert | |
| WO2012118802A9 (en) | Kit and method for sequencing a target dna in a mixed population | |
| WO2011087709A2 (en) | Eml4-alk translocations in lung cancer | |
| DE602004004988T2 (de) | Methylierungsstatus-Detektionsassays mittels methylierungsspezifischer Primerextension (MSPE) | |
| DE69424209T2 (de) | Tumorsuppressor-Gen Merlin und dessen Verwendungen | |
| DE69736475T2 (de) | Quantifizierung von rna-transkripten mittels genomischer dna als internen standard der amplifizierungsreaktion | |
| Szibor et al. | Mitochondrial D‐loop 3′(CA) n repeat polymorphism: Optimization of analysis and population data | |
| CN106536758A (zh) | 利用夹紧探针及检测探针的多靶核酸检测方法的应用 | |
| Ooi et al. | Ha-ras codon 12 mutation in papillary tumors of the urinary-bladder-a retrospective study | |
| DE69434809T2 (de) | Bc200 rna, daraus abgeleitete proben und entsprechende anwendungen | |
| WO2012003950A1 (de) | Nachweis von mutationen, insbesondere deletionen oder insertionen | |
| KR20070031925A (ko) | 유방암 경과의 진단 또는 예측 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |